News & Media
Center for Breakthrough Medicines (CBM) Expands Contract Testing Services with the launch of the Analytical Accelerator™ for AAV Testing to Serve Growing Pipeline of Gene Therapies
The Center for Breakthrough Medicines (CBM), announced today the launch of their Analytical AcceleratorTM for AAV Testing to help gene therapy developers meet the quality domains of identity, safety, purity, potency, and stability required by the Food and Drug Administration (FDA) and global regulatory authorities.
Center for Breakthrough Medicines and jCyte Announce Strategic Partnership to Manufacture jCyte’s Innovative Cell Therapy for Treatment of Retinal Degenerative Diseases
Center for Breakthrough Medicines and jCyte Announce Strategic Partnership to Manufacture jCyte’s Innovative Cell Therapy for Treatment of Retinal Degenerative Diseases.
CBM has appointed of Mandy Conver as Senior Vice President (SVP) of Business Development for Testing & Analytics, and Jennifer Manning as (SVP) of Global Strategic Partnerships.
Center for Breakthrough Medicines Accelerates Plans to Build the Largest Cell Therapy Manufacturing Operation in the World
The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs announced today the acceleration of plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer.
iECURE Enters Agreement with Center for Breakthrough Medicines (CBM) to Supply Materials for Future Clinical Programs
iECURE, a gene editing company focused on mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, and Center for Breakthrough Medicines (CBM) today announced the companies have entered into a strategic collaboration wherein CBM will produce and supply Good Manufacturing Practices (GMP)-grade adeno-associated virus (AAV) for use in iECURE’s future clinical studies to enable development of iECURE’s programs.
Strategic Partnership to Deliver US Based Manufacturing Capacity for Novel Cell Therapy King of Prussia